High prevalence of insomnia and insomnia symptoms in patients with T2D

  • Koopman ADM & al.
  • J Clin Endocrinol Metab
  • 11 Oct 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This meta-analysis found a high prevalence of insomnia and symptoms of insomnia in patients with type 2 diabetes (T2D), which may be associated with deleterious glycaemic control.

Why this matters

  • Findings suggest that efforts towards educating patients with T2D about the importance of sleep could be the first strategy to improve glycaemic control.

Study design

  • Meta-analysis of 78 studies assessed the prevalence of insomnia symptoms and its association with metabolic parameters or glycaemic control in patients with T2D.
  • Funding: None disclosed. 

Key results

  • The prevalence of insomnia and insomnia symptoms was 39% in patients with T2D (95% CI, 34-44%; I2=100%; P<.00001>
  • Prevalence was higher in the Asian population compared with the European/American population (49% vs 40%).   
  • Patients with T2D with insomnia vs those without insomnia had higher:
    • HbA1c levels (mean difference [MD], 0.23%; 95% CI, 0.1-0.4%; I2=76%; P<.00001 risk ratio ci i>2=73%; P=.001),
    • fasting glucose levels (MD, 0.40 [95% CI, 0.2-0.7] mmol/L; I2=57%; P=.01),
    • body mass index (MD, 0.38 [95% CI, 0.1-0.7] kg/m2; I2=47%; P=.03) and
    • total cholesterol levels (MD, 0.15 [95% CI, 0.03-0.3] mmol/L; P=.43).

Limitations

  • High heterogeneity across studies. 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit